David Foy, DO
Family Medicine · Phoenix, AZNPI 1497747448
Payments from drug & device makers
Across 163 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$799
- AbbVie$579
- Novo Nordisk$388
- Abbott$332
- Teva Pharmaceuticals USA, Inc.$255
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$176
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,779100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $799 |
| AbbVie(2 entities) | 35 | $579 |
| Novo Nordisk | 8 | $388 |
| Abbott | 11 | $332 |
| Teva Pharmaceuticals USA, Inc. | 10 | $255 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $176 |
| Idorsia Pharmaceuticals US Inc | 5 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $150 |
| Lilly USA, LLC | 10 | $148 |
| Boston Scientific | 3 | $137 |
| Antares Pharma, Inc. | 7 | $109 |
| Pfizer | 5 | $89 |
| Eisai Inc. | 3 | $59 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Merck | 3 | $43 |
| Boehringer Ingelheim | 2 | $42 |
| GSK | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Almatica Pharma LLC | 2 | $34 |
| Baxter Healthcare | 1 | $29 |
| Nevro Corp. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Phadia US Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,785 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 46 | $46,887 |
| TrulicityDulaglutide | 42 | $41,045 |
| OzempicSemaglutide | 22 | $31,181 |
| EliquisApixaban | 29 | $27,787 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $21,156 |
| JardianceEmpagliflozin | 13 | $12,881 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $4,249 |
| Varenicline Tartrate | 11 | $4,244 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,703 |
| Atorvastatin Calcium | 216 | $2,636 |
| Bupropion XlBupropion Hcl | 56 | $2,170 |
| Gabapentin | 104 | $2,153 |
| Levothyroxine Sodium | 164 | $1,763 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $1,629 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 108 | $1,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $148 | $87,93288 claims |
| Novo NordiskOzempic | $388 | $31,18122 claims |
| PfizerEliquis | $89 | $27,78729 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $37 | $24,86042 claims |
| Boehringer IngelheimJardiance | $42 | $12,88113 claims |
| AbbVieSynthroid | $579 | $1,41817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Brock MerrittPhoenix$8.4M
- Douglas CunninghamPhoenix$4.9M
- Jeffrey ZacherPhoenix$2M
- Trisha TavaresPhoenix$1.6M
- David FrancykPhoenix$1.3M
- James BeachPhoenix$1.2M
- Peter LevinsPhoenix$971K
- Elysa ShawPhoenix$774K
- Mitchell EdelsteinPhoenix$741K
- Brian DedinskyPhoenix$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.